Original paper

Clinical utility of MCM2 and CD44 expression in clear cell renal cell carcinoma

Mariana F. Gavyed\(^1\*\), Medhat M. Soliman\(^2\), Maram El-Hussieny\(^1\)*

\(^1\)Faculty of Medicine, Minia University, Minia, Egypt
\(^2\)Minia Oncology Center, Minia, Egypt

*These two authors equally contributed to this work.

Clear cell renal cell carcinoma (ccRCC) has an unpredictable clinical consequence even with the use of usual prognostic factors. To determine whether utilization of cell proliferation and cell adhesion by using MCM2 and CD44 immuno-expression could predict the biological performance of ccRCC.

MCM2 and CD44 protein expression levels in tumor tissues from 120 ccRCC patients were evaluated by immunohistochemistry. The relationships between MCM2 and CD44 expression and clinicopathological parameters were evaluated. The overall survival (OS) was computed by the Kaplan-Meier method. The role of MCM2 and CD44 in the prognosis was estimated by univariate and multivariate Cox regressions. The results showed high MCM2 and CD44 protein expression levels in 63.3% and 55% of ccRCC cases, respectively. MCM2 and CD44 over-expression was significantly related to tumor grade (p = 0.001 and p = 0.003, respectively), T stage (p = 0.005 and p = 0.008, respectively), lymph node status (p = 0.015 and p = 0.040, respectively), AJCC stage (p = 0.000 and p = 0.002, respectively) and OS (p = 0.019 and p = 0.001, respectively). Multivariate Cox regression showed that high MCM2 and CD44 expression levels were independently associated with prognosis of ccRCC cases (HR = 2.687, 2.810, 95% CI: 1.217-5.920, 1.267-6.233, respectively).

MCM2 and CD44 are considered as independent risk and poor prognostic factors for the prognosis of ccRCC patients.

Key words: ccRCC, MCM2, CD44, immunohistochemistry, prognosis.

Introduction

Renal cancer accounts for about 3% of all adult malignant tumors. It is the 12\(^{th}\) most common malignancy worldwide [1]. Renal cell carcinoma (RCC) represents about 85% of all renal cancers. The majority of RCC are clear cell renal cell carcinoma (ccRCC) [2].

Although most of the patients with RCC are diagnosed with an early stage tumor, still about 25% of cases present with a locally advanced and/or metastatic disease. A proportion of patients who underwent nephrectomy developed either recurrence or metastasis [3]. The clinical outcomes of RCC differ widely, indicating the need for appropriate and accurate prognostic parameters. To date, the best prognostic system for overall survival (OS) is the TNM staging system; however, it isn’t enough to significantly enhance the management of patients. There-
fore, detection of novel reliable prognostic factors is vital for improving therapeutic strategies in order to prolong the survival of RCC patients [4, 5].

Minichromosome maintenance (MCM) protein 2 is one of 6 proteins that form the MCM complex. It has a vital role in DNA replication. MCM2 and other MCM proteins are targets of ATR (ataxia telangiectasia and Rad3 related) and ATM (ataxia telangiectasia mutated) genes that inhibit DNA replication and initiate repair [6]. MCM proteins stay stable throughout the cell cycle but their levels decrease during cellular differentiation. This could be attributed to the presence of the pre-replication complex throughout the cell cycle. This makes these proteins suitable candidates as indicators of proliferation [7].

Previous studies had observed that MCM2 serves as a proliferation marker of malignant cells. High expression levels of it in malignant tumors were associated with several clinicopathological characteristics such as advanced stage, high grade and poor prognosis [8, 9, 10].

CD44 is a transmembrane glycoprotein with multiple isoforms, among them CD44 standard (CD44s). The extracellular domain of CD44 is the principal receptor for hyaluronic acid. In tumors, CD44s bound with hyaluronic acid targets numerous processes such as progression, proliferation, invasion and metastasis [11, 12].

CD44 is an important cancer stem cell marker and a poor prognostic marker in various malignancies. It helps in various seeps which are fundamental in extravasation and migration of neoplastic cells. The interactions between CD44 cytoplasmic tail and actin cytoskeleton could be stimulated via CD44–HA binding; so, migration of tumor cells is initiated [13, 14].

In the current study we aimed to evaluate the cross-talk between these two markers in ccRCC and to correlate MCM2 and CD44 expression with clinicopathological parameters and survival of the patients in a trial to explore their significance as suggested indicators for tumor progression, recurrence and patients’ prognosis.

Material and methods

Case selection and tissue sample preparation

In this retrospective study, one hundred twenty cases of ccRCC were randomly selected from the archive of the pathology lab of Minia University Hospital and Minia Oncology Center during the period of January 2010 to August 2014. Paraffin blocks with clinicopathological data of the patients were collected including: patient’s age, gender, tumor size, AJCC clinical stage, N stage and TNM stage. HE slides were prepared to detect Fuhrman nuclear grade.

Immunohistochemistry

Sections were cut 4 μm thick on positively charged slides, de-paraffinized with xylene and rehydrated through graded ethanol. Slides were immersed in 3% hydrogen peroxide for 30 min to quench endogenous peroxidase then rinsed in PBS solution. Treatment in citrate buffer (pH 6.0) was done for antigen retrieval using the microwave. Afterwards, slides were left to cool at room temperature and washed in PBS solution. Mouse monoclonal anti-MCM2 (BioSpring) and mouse monoclonal anti-CD44 (Thermo-Fisher) antibodies were added. Sections incubated overnight at 4°C in a humidity chamber and then rinsed with PBS before treatment with secondary antibody for 30 min. After a wash in PBS, the streptavidin-biotin complex reagent was added for 30 min. Brownish color was developed by using 3,3-diaminobenzidinetetrahydrochloride (DAB), then slides were washed in distilled water, stained with hematoxylin, dehydrated, cleared with xylene, and coverslipped.

Evaluation of immunostaining

Slides were examined by two pathologists (M. Gayyed and M. El-Husseiny), independently who were blinded to clinicopathological data of the cases. Concerning MCM2, nuclear staining was considered positive. For quantitative analysis hot spots were detected by low power. Then stained cells were counted in 10 high-power fields chosen randomly. The LI was expressed as the percentage of positively stained cells based on a count of at least 1,000 cancer cells. A labeling index more than 20% was used as a cutoff point [7, 15].

The CD44 was stated as percentages of the CD44-positive cells by counting at least 1,000 tumor cells at ×400. CD44 was considered positive when membranous/cytoplasmic expression was detected in > 5% of the stained cells [16]. Sections were scored for the CD44 staining patterns as follows: the staining extent was scored as 0 (0-5% staining of tumor cells), 1+ (> 5% - < 25% staining of tumor cells), 2+ (25-50% staining of tumor cells), 3+ (50-75% staining of tumor cells) or 4+ (> 75% staining of tumor cells). Scores of 0 and 1+ were regarded as exhibiting low expression and scores of 2+, 3+ and 4+ were judged as exhibiting high expression [11].

Statistical analysis

Data were analyzed using SPSS version 20. Chi-square and Fisher’s exact tests were used to compare categorical variables. Correlation between MCM2 and CD44 was evaluated using Spearman’s correlation coefficient. Analysis of OS was examined by the Kaplan-Meier method. The effect of MCM2 and CD44 on the prognosis of ccRCC patients was assessed via univariate and multivariate Cox regression.
Hazard risk (HR) and relative 95% confidence interval (CI) were analyzed. Results were considered statistically significant when p-value ≤ 0.05.

Results

This study was performed on 120 patients with ccRCC. The age of patients ranged from 29 years to 79 years with a mean (± standard deviation: SD) of 52.72 ± 1.28 years and a median of 54 years. The tumor size ranged from 3 cm to 16 cm with a mean (±standard deviation: SD) of 7.016 cm ± 2.6 and a median of 7 cm. Other patients’ characteristics are shown in Table I.

MCM2 immunoreactivity

MCM2 expression was detected in the nucleus as shown in (Fig. 1). MCM2 overexpression was low in 44 cases (36.7%) and high in 76 cases (63.3%). MCM2 high expression was significantly associated with high tumor grade (p = 0.001), tumor stage (p = 0.005), nodal status (p = 0.015), AJCC stage (p = 0.000) and overall survival (p = 0.019). No association was found between MCM2 immunoreactivity and other clinicopathological characteristics, as shown in Table II.

CD44 immunoreactivity

The CD44 protein was distributed in the membrane ± cytoplasm of the tumor cells, as shown in Fig. 1. CD44 expression was low in 54 cases (45%) and high in 66 cases (55%). The CD44 immunostaining was significantly associated with high tumor grade (p = 0.003), tumor stage (p = 0.008), lymph node status (p = 0.040), high tumor AJCC stage (p = 0.002) and overall survival (p = 0.001). No association was found between CD44 expression and other clinicopathological characteristics (Table II).

MCM2 and CD44

No statistically significant association was found between MCM2 and CD44 (p = 940 and r = 0.007).

Survival analysis

The follow-up ranged from 12 months to 59 months with a mean (±standard deviation: SD) of 42.9 ± 1.06 months and a median of 46 months. Overall survival was not significantly associated with any prognostic clinicopathological factors. Regarding marker expression and OS, increased expression levels of MCM2 and CD44 were associated with worse OS (p = 0.019 and 0.001 respectively; Fig. 2).

The relationship between the prognosis and the expression of MCM2 and CD44 in ccRCC cases was evaluated via univariate and multivariate Cox regression. The univariate regression (Table III) indicated that tumor size (HR = 2.383, 95% CI: 1.189-4.774, p = 0.014), grade (grade III: HR = 2.876, 95% CI: 1.107-7.472, p = 0.030), AJCC stage (stage III: HR = 2.252, 95% CI: 1.042-4.870, p = 0.039), high MCM2 expression (HR = 3.313, 95% CI: 1.019-10.771, p = 0.046) and high CD44 expression (HR = 3.456, 95% CI: 1.000-11.947, p = 0.05) were all associated with survival status of ccRCC patients. The multivariate regression (Table IV) showed that positive MCM2 and CD44 expression significantly increased the risk of adverse consequences (HR = 2.687, 95% CI: 1.217-5.930,
Discussion

The clinical outcome of ccRCC is problematic and its prognosis can be diverse even with analogous pathological descriptions. Therefore, it is important to create a more accurate prognostic model including molecular and genetic biomarkers alongside traditional prognostic markers such as histopathological features and the TNM staging system [17]. Moreover, molecular-based biomarkers not only have benefits in expecting prognosis, but also have promising

Fig. 1. Immunohistochemical expression of MCM2 and CD44 in ccRCC. Increased nuclear MCM2 expression (A) is associated with increased CD44 expression (B) (the first row). Cases with low MCM2 expression (C) have low CD44 expression (D) (the second row) (magnification 200×).

Fig. 2. Kaplan-Meier survival curves for overall survival according to MCM2 and CD44 expression. Shorter OS is associated with high MCM2 and CD44 expression.

\( p = 0.014 \) and HR = 2.810, 95% CI: 1.267-6.233, \( p = 0.011 \); Fig. 3).
MCM2 and CD44 expression in clear cell renal cell carcinoma

Possibility for usage as a postoperative targeted therapy in high-risk patients.

MCM2-7 are the main players in the initiation of DNA replication by formation of what is called a pre-replicative protein complex. They wind down the DNA helix, an essential step for the initiation of DNA manufacture. MCM2 only lets this replication occur when the cell cycle is completed [18]. This gene plays an essential role in the development of many types of cancers and has been linked to enhanced proliferation in cancer [19].

To our knowledge, this is the first study to evaluate the expression of MCM2 in clear cell variant of RCC. In the current study, high MCM2 expression was detected in 63.3% of ccRCC. Also, we found a significant association between MCM2 immunexpression and the clinical prognostic factors tumor grade, T stage, lymph node status, AJCC stage and OS (p = 0.001, p = 0.005, p = 0.015, 0.000 and 0.019 respectively). There was no statistically significant difference in MCM2 expression in relation to the other clinicopathological features of the cases.

### Table II. Association between CD44 and MCM2 expression and clinicopathological characteristics of ccRCC cases (n = 120)

| CLINICOPATHOLOGICAL CHARACTERISTICS | CD44 EXPRESSION | MCM2 EXPRESSION |
|------------------------------------|-----------------|-----------------|
|                                    | Low (%)         | High (%)        | Low (%)         | High (%)        |
| Age (years)                        |                 |                 |                 |                 |
| ≤ 54                               | 21 (39.6%)      | 32 (60.4%)      | 23 (43.4%)      | 30 (56.6%)      |
| > 54                               | 33 (49.3%)      | 34 (50.7%)      | 21 (31.3%)      | 46 (68.7%)      |
| Gender                             |                 |                 |                 |                 |
| Male                               | 36 (46.8%)      | 41 (53.2%)      | 26 (33.8%)      | 51 (66.2%)      |
| Female                             | 18 (41.9%)      | 25 (58.1%)      | 18 (41.9%)      | 25 (58.1%)      |
| Tumor size (cm)                    |                 |                 |                 |                 |
| < 7 cm                             | 27 (36.5%)      | 47 (63.5%)      | 32 (43.2%)      | 42 (56.8%)      |
| ≥ 7 cm                             | 27 (58.7%)      | 19 (41.3%)      | 12 (26.1%)      | 34 (73.9%)      |
| Tumor grade                        |                 |                 |                 |                 |
| GI                                 | 18 (100%)       | 0 (0%)          | 18 (100%)       | 0 (0%)          |
| GII                                | 23 (56.1%)      | 18 (43.9%)      | 15 (36.6%)      | 26 (63.4%)      |
| GIII                               | 6 (13.6%)       | 38 (86.4%)      | 6 (13.6%)       | 38 (86.4%)      |
| GIV                                | 7 (41.2%)       | 10 (58.8%)      | 5 (29.4%)       | 12 (70.6%)      |
| T Stage                            |                 |                 |                 |                 |
| T1                                 | 19 (82.6%)      | 4 (17.4%)       | 19 (82.6%)      | 4 (17.4%)       |
| T2                                 | 32 (64%)        | 18 (36%)        | 20 (40%)        | 30 (60%)        |
| T3                                 | 2 (4.5%)        | 42 (95.5%)      | 4 (9.1%)        | 40 (90.0%)      |
| T4                                 | 1 (33.3%)       | 2 (66.7%)       | 1 (33.3%)       | 2 (66.7%)       |
| N Stage                            |                 |                 |                 |                 |
| N0                                 | 53 (47.7%)      | 58 (52.3%)      | 44 (39.6%)      | 67 (60.4%)      |
| N1, N2                             | 1 (11.1%)       | 8 (88.9%)       | 0 (0%)          | 9 (100%)        |
| AJCC Clinical stage                |                 |                 |                 |                 |
| Stage I                            | 14 (87.5%)      | 2 (12.5%)       | 13 (81.2%)      | 3 (18.8%)       |
| Stage II                           | 31 (67.4%)      | 15 (32.6%)      | 20 (43.5%)      | 26 (56.5%)      |
| Stage III                          | 7 (19.4%)       | 29 (80.6%)      | 6 (16.7%)       | 30 (83.3%)      |
| Stage IV                           | 2 (9.1%)        | 20 (90.9%)      | 5 (22.7%)       | 17 (77.3%)      |
| Overall survival                   |                 |                 |                 |                 |
| Censored                           | 42 (63.6%)      | 24 (36.4%)      | 33 (50%)        | 33 (50%)        |
| Event                              | 12 (22.2%)      | 42 (77.8%)      | 11 (20.4%)      | 43 (79.6%)      |

*Test of significance: χ² and Fisher exact tests p-value < 0.05 is considered significant.
In line with our findings, Dudderidge et al. detected a statistically significant association between MCM2 expression and tumor grade. They also found a strong hint suggesting that increased MCM2 expression was linked to reduced disease-free survival in RCC [20].

Also, Zhong et al. (2017) stated that high expression of the MCM2 gene in either primary RCC or its metastasis was significantly associated with a shorter disease-free survival time [21]. Another study done by Giaginis et al. (2009) showed that a statistically significant relation was determined between MCM2 expression and tumor grade and stage in colon cancer [22].

Cancer stem cells (CSCs) have been identified in several tumors including hepatic, ovarian, prostatic, bladder, breast and pancreatic cancers [23]. They are characterized by extensive self-renewal ability and pluripotent differentiation ability. There is strong evidence for crosstalk between tumor progression, metastasis and stem cells; however, the importance of stem cell marker overexpression in cancer is still vague and needs further clarification [24]. Cancer stem cells are believed to be resistant to chemotherapy as well as radiotherapy, although the mechanisms are not fully understood [25]. So, they could be the therapeutic target of cancers [26].

### Table III. Univariate Cox regression analysis of relationship between clinicopathological characteristics and prognosis in cases of ccRCC

| Characteristic | B    | SE   | Wald | P Value | Exp(B) | 95.0% CI Lower | 95.0% CI Upper |
|---------------|------|------|------|---------|--------|----------------|----------------|
| Age           | -0.228 | 0.303 | 0.567 | 0.451  | 0.796  | 0.440  | 1.441       |
| Sex           | 0.178 | 0.332 | 0.288 | 0.592  | 1.195  | 0.624  | 2.288       |
| Size          | 0.868 | 0.355 | 5.996 | 0.014  | 2.383  | 1.189  | 4.774       |
| Grade         | 8.789 | 0.032 |       |         |        |               |               |
| Grade I       | -2.044 | 1.388 | 2.167 | 0.141  | 0.130  | 0.009  | 1.968       |
| Grade II      | 0.132 | 0.486 | 0.074 | 0.785  | 1.142  | 0.440  | 2.959       |
| Grade III     | 1.056 | 0.487 | 4.704 | 0.030  | 2.876  | 1.107  | 7.472       |
| T1            |       |       | 6.244 | 0.100  |        |               |               |
| T2            | -0.673 | 1.042 | 0.417 | 0.518  | 0.510  | 0.066  | 3.935       |
| T3            | 0.840 | 0.795 | 1.116 | 0.291  | 2.317  | 0.487  | 11.017      |
| LN            | -0.655 | 0.431 | 2.305 | 0.129  | 0.520  | 0.223  | 1.210       |
| AJCC stage    | 15.611 | 0.001 |       |         |        |               |               |
| Stage I       | -1.371 | 0.884 | 2.404 | 0.121  | 0.254  | 0.045  | 1.436       |
| Stage II      | -1.048 | 0.497 | 4.443 | 0.035  | 0.351  | 0.132  | 0.929       |
| Stage III     | 0.812 | 0.393 | 4.261 | 0.039  | 2.252  | 1.042  | 4.870       |
| MCM2          | 1.198 | 0.602 | 3.966 | 0.046  | 3.313  | 1.019  | 10.771      |
| CD44          | 1.240 | 0.633 | 3.839 | 0.050  | 3.456  | 1.000  | 11.947      |

### Table IV. Multivariate Cox regression analysis of relationship between clinicopathological characteristics and prognosis in cases of ccRCC

| Characteristic | B    | SE   | Wald | p-value | Exp(B) | 95.0% CI Lower | 95.0% CI Upper |
|---------------|------|------|------|---------|--------|----------------|----------------|
| Size          | -0.546 | 0.321 | 2.893 | 0.089  | 0.579  | 0.309  | 1.087       |
| Grade         | 0.114 | 0.207 | 0.306 | 0.580  | 1.121  | 0.748  | 1.681       |
| AJCC stage    | 0.239 | 0.194 | 1.528 | 0.216  | 1.270  | 0.869  | 1.856       |
| MCM2          | 0.988 | 0.404 | 5.986 | 0.014  | 2.687  | 1.217  | 5.930       |
| CD44          | 1.033 | 0.406 | 6.462 | 0.011  | 2.810  | 1.267  | 6.233       |
CD44 is a cell surface transmembrane glycoprotein that plays a role as a cell adhesion molecule and a receptor for hyaluronic acid. It has a role in tumor cell invasion and metastasis by intermingling with extracellular matrix metalloproteinases. CD44 was used as an indicator of tumor aggressive behavior in malignancy [27]. CD44 was first described as a CSC marker in breast cancer [28]. However, it has limited utility as a CSC marker or prognostic factor in ccRCC.

In this study, we found high CD44 expression in 66 cases (55%), and this was in accordance with what was reported by Qin et al., who found high CD44 expression in 46.67% of cases [29]. In the current work a statistically significant association between CD44 immunostaining and high tumor grade (p = 0.003), tumor stage (p = 0.008), lymph node status (p = 0.040) and high tumor AJCC stage (p = 0.002) was detected. These results were in line with Paradis et al., who reported a link between CD44 and grade and T stage [30]. No statistically significant difference in CD44 expression was found in relation to the other clinicopathological features of the patients.

In the current work a significant association was found between CD44 and OS (p = 0.001). This was in line with Qin et al., who reported CD44 as an independent predictor of OS in their research [29], while another study found that it was not an independent predictor of survival but they found a significant association with the poor prognostic factors clinical stage and Fuhrman grade [30].

Multivariate analysis indicated that positive MCM2 and CD44 expressions were independent risk factors of prognosis in ccRCC patients, suggesting that high MCM2 and CD44 expressions are molecular markers of poor prognosis in ccRCC patients.

Our study revealed no significant correlation between MCM2 and CD44. To our knowledge no previous work has evaluated this relation.

Fig. 3. Univariate (A, B) and multivariate (C, D) Cox regression survival curves according to MCM2 and CD44 expression.
In conclusion, this study suggests that increased cell proliferation demonstrated by high immunohistochemical expression of MCM2 and cell adhesion investigated through increased level of CD44 in ccRCC is related to adverse prognosis.

The authors declare no conflict of interest.

References

1. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. International Agency for Research on Cancer. V1.0, Lyon 2012. Available from: http://globocan.iarc.fr.

2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1999; 49: 8-33.

3. Ficarra V, Galliano A, Novara G, et al. Risk stratification and prognostication of renal cell carcinoma. World J Urol 2008; 26: 115-125.

4. Kim SP, Alt AI, Weight CJ, et al. Independent validation of the 2010 American Joint Committee on Cancer TNM classification for renal cell carcinoma: results from a large, single institution cohort. J Urol 2011; 185: 2035-2039.

5. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474.

6. Cortez D, Glick G, Elledge SJ. Minichromosome maintenance proteins are direct targets of the ATM and ATR checkpoint kinases. Proc Natl Acad Sci U S A 2004; 101: 10078-10083.

7. Mehdiz MZ, Nagi AH, Naseem N. MCM-2 and Ki-67 as proliferation markers in renal cell carcinoma: A quantitative and semi-quantitative analysis. Int Braz J Urol 2016; 42: 1121-1128.

8. Davies RJ, Freeman A, Morris LS, et al. Analysis of minichromosome maintenance proteins as a novel method for detection of colorectal cancer in stool. Lancet 2002; 359: 1917-1919.

9. Gakipoupolou H, Korkolopoulou P, Levidou G, et al. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. Br J Cancer 2007; 97: 1124-1134.

10. Abe S, Yamamoto K, Kurata M, et al. Targeting MCM2 function as a novel strategy for the treatment of highly malignant breast tumors. Oncotarget 2015; 6: 34892-34909.

11. He Y, Xue C, Yu Y, et al. CD44 is overexpressed and correlated with tumor progression in gallbladder cancer. Cancer Manag Res 2018; 10: 3857-3865.

12. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010; 46: 1271-1277.

13. Li X, Ma X, Chen L, et al. Prognostic value of CD44 expression in renal cell carcinoma: a systematic review and meta-analysis. Sci Rep 2015; 5: 13157.

14. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011; 11: 254-267.

15. Rodinis K, Cheale M, Coleman N, Fox SB. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin Cancer Res 2002; 8: 1073-1081.

16. Noroozinia F, Fahmideh AN, Yekta Z, et al. Expression of CD44 and P53 in renal cell carcinoma: association with tumor subtypes. Saudi J Kidney Dis Transpl 2014; 25: 79-84.

17. Parker AS, Leibovich BC, Lohse CM, et al. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009; 115: 2092-2103.

18. Gueiros LA, Coletta RD, Kowalski LP, Lopes MA. Clinicopathological features and proliferation markers in tongue squamous cell carcinomas. Int J Oral Maxillofac Surg 2011; 40: 510-515.

19. Gouvea AF, Santos Silva AR, Speight PM, et al. High incidence of DNA ploidy abnormalities and increased Mcm2 expression may predict malignant change in oral proliferative verrucous leukoplakia. Histopathology 2013; 62: 551-562.

20. Duddridge TJ, Stoeber K, Loddo M, et al. Mcm2, Gemmini, and KI67 define proliferative state and are prognostic markers in renal cell carcinoma. Clin Cancer Res 2005; 11: 2510-2517.

21. Zhong H, Chen B, Neves H, et al. Expression of minichromosome maintenance genes in renal cell carcinoma. Cancer Manag Res 2017; 9: 637-647.

22. Giaginis C, Georgiadou M, Dimakopoulou K, et al. Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity. Digestive Dis Sci 2009; 54: 282-291.

23. Pereira JS, Barroso KMA, Nonaka CF, et al. Immunoeexpression of cell proliferation markers in oral squamous cell carcinoma. Int J Odontostomatot 2016; 10: 513-520.

24. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.

25. Yin X, Zhang BH, Zheng SS, et al. Coexpression of gene Ocr4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Stat3 signaling. J Hematol Oncol 2015; 8: 23.

26. Tanaka S. Cancer stem cells as therapeutic targets of hepatobiliary-pancreatic cancers. J Hepatobiliary Pancreat Sci 2015; 22: 531-537.

27. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45.

28. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988.

29. Qin J, Yang B, Xu BQ, et al. Concurrent CD44s and STAT3 expression in human clear cell renal cellular carcinoma and its impact on survival. Int J Clin Exp Pathol 2014; 7: 3235-3244.

30. Costa WH, Rocha RM, Cunha IW, et al. Immunohistochemical expression of CD44s in renal cell carcinoma lacks independent prognostic significance. Int Braz J Urol 2012; 38: 456-465.

Address for correspondence
Mariana F. Gayyed
Assistant Professor of Pathology
Faculty of Medicine
Minia University
61511 Minia, Egypt
e-mail: mariana.gaid@mu.edu.eg